Plus Therapeutics Inc

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Plus Therapeutics advances trials, secures funding, and expands diagnostics

Plus Therapeutics demonstrates strong financial and operational progress with successful funding, grants, and trial advancements.
Strategic additions to the management team and diagnostic capabilities enhance the company's expertise and market positioning.
Challenges in financial management, regulatory processes, and dosing strategies require careful navigation for sustained growth and success.
Opportunities lie in FDA feedback, commercial launches, collaborations, and positive trial outcomes for future growth and market impact.

Plus Therapeutics Inc (PSTV) reports clinical progress amidst financial challenges

Plus Therapeutics Inc (PSTV) made significant clinical advancements in Q2 2024, while facing financial challenges. The company's strengths include positive trial results and supportive conference data, with opportunities for growth through expanded capabilities and funding access.

Plus Therapeutics progresses in leptomeningeal metastases program with strong financial backing

Plus Therapeutics is advancing promising treatments for leptomeningeal metastases with encouraging clinical data and FDA support.
Financially, the company is well-positioned with a solid cash balance, expected grant revenue, and access to diverse funding sources.
Strategic focus on upcoming events, milestones, and product launches underscores the company's commitment to innovation and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After losing some value lately, a hammer chart pattern has been formed for Plus (PSTV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q2 2023 Earnings Conference Call August 14, 2023 5:00 PM ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Chief Financial Officer Conference Call Participants Justin Walsh - Jones Trading Sean Lee - H.C. Wainwright Edward Woo - Ascendiant Capita Operator Good afternoon, ladies and gentlemen.

Plus Therapeutics, Inc. (PSTV) Q2 2023 Earnings Call Transcript

ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma

Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases

Plus Therapeutics Reports ReSPECT-LM Phase 1 Trial Data at the 2023 SNO/ASCO CNS Cancer Conference

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

Plus Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 14, 2023

Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial

Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the Canaccord Genuity 43rd Annual Growth Conference, on Wednesday, August 9, 2023 at 8:00 a.m. ET at the InterContinental Boston in Boston, Mass.

Plus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts.

Plus Therapeutics to Present at the 2nd Annual Targeted Radiopharmaceuticals Summit

ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose

Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting

NEW YORK--(BUSINESS WIRE)-- #IR--ICR, a leading strategic communications and advisory firm, is pleased to announce that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, recently appeared on Episode 81 of ICR's “Welcome to the Arena” podcast. Welcome to the Arena is hosted by Tom Ryan, Co-Founder &.

ICR Hosts Plus Therapeutics CEO Marc Hedrick on the Welcome to the Arena Podcast

AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to participate in a fireside chat at the 2023 Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21, 2023 at 3:30 p.m. ET.

Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

Company to showcase pipeline developments across lead programs in recurrent glioblastoma and leptomeningeal metastases in two poster presentations at SNMMI Annual Meeting Company to showcase pipeline developments across lead programs in recurrent glioblastoma and leptomeningeal metastases in two poster presentations at SNMMI Annual Meeting

Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting

Presentation at 2023 Virtual June Investor Summit to highlight clinical development progress Presentation at 2023 Virtual June Investor Summit to highlight clinical development progress

Plus Therapeutics Provides Company Update Today

Plus Therapeutics' partnership with Medidata resulted in a valid historical control arm for the Company's Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM)

Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Marc Hedrick, M.D., President and Chief Executive Officer, will present at the 2023 Virtual June Investor Summit on Thursday, June 1, 2023, at 2:00 p.m. ET.

Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that it has received notification from The Nasdaq Stock Market LLC that the staff has determined that for the last 10 consecutive business days, from May 1, 2023 to May 12, 2023, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Therefore, the Company has regained compliance with Listing Rule 5550(a)(2). Accordingly, Nasdaq has advised that the matter is now closed.

Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements

New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic

Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company's existing trading symbol, “PSTV.” At such time, the Company's common stock will also commence trading with a new CUSIP number, 72941H509.

Plus Therapeutics Announces Reverse Stock Split

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript.

Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates

Plus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights.

Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Presentation of data from ReSPECT-GBM Phase 1/2a and Phase 2b trials expected second half of 2023 Presentation of data from ReSPECT-GBM Phase 1/2a and Phase 2b trials expected second half of 2023

Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

AUSTIN, Texas, April 18, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today that Norman LaFrance, M.D., Chief Medical Officer and Senior Vice President, will participate as a panel presenter at the Canaccord Genuity Horizons in Oncology Virtual Conference.

Plus Therapeutics to Participate in Panel at the Canaccord Genuity Horizons in Oncology Virtual Conference

The Company plans to meet with U.S. FDA to discuss next steps for the Phase 1/Part B trial in the third quarter of 2023

Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases

AUSTIN, Texas, April 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report first quarter 2023 financial results on Thursday, April 20, 2023, after market close. Plus Therapeutics' management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.

News for Plus Therapeutics Inc Stock (PSTV)